Perm Medical JournalPerm Medical JournalПермский медицинский журнал (сетевое издание "Perm medical journal")0136-14492687-1408Eco-Vector64934510.17816/pmj4235-16Literature reviewОбзор литературыReview ArticleSarcopenia as a complication of type 1 diabetes mellitusСаркопения как осложнение сахарного диабета 1-го типаhttps://orcid.org/0000-0003-4663-02897456-5920MakarovaOlga B.МакароваОльга Борисовна
Russian Federation

DSc (Medicine), Associate Professor, Associate Professor of the Department of Therapy with Courses in Endocrinology, Functional and Ultrasound Diagnostics of the Institute of Clinical Medicine

доктор медицинских наук, доцент, доцент кафедры терапии с курсами эндокринологии, функциональной и ультразвуковой диагностики Института клинической медицины

dr.makarova@yahoo.comhttps://orcid.org/0009-0008-0110-57089077-3713LyapunovaAnastasia I.ЛяпуноваАнастасия Игоревна
Russian Federation

Clinical Resident of the Department of Therapy with Courses in Endocrinology, Functional and Ultrasound Diagnostics of the Institute of Clinical Medicine

клинический ординатор кафедры терапии с курсами эндокринологии, функциональной и ультразвуковой диагностики Института клинической медицины

dr_lyapunova@mail.ruhttps://orcid.org/0000-0001-9253-80751212-5397SuplotovaLyudmila A.СуплотоваЛюдмила Александровна
Russian Federation

DSc (Medicine), Professor, Head of the Courses in Endocrinology, Functional and Ultrasound Diagnostics of the Institute of Clinical Medicine

доктор медицинских наук, профессор, заведующая курсом эндокринологии кафедры терапии с курсами эндокринологии, функциональной и ультразвуковой диагностики Института клинической медицины

suplotovala@mail.ruhttps://orcid.org/0000-0002-1232-38069487-3834AlievaOksana O.АлиеваОксана Олимжоновна
Russian Federation

Postgraduate Student of the Department of Therapy with Courses in Endocrinology, Functional and Ultrasound Diagnostics of the Institute of Clinical Medicine

аспирант кафедры терапии с курсами эндокринологии, функциональной и ультразвуковой диагностики Института клинической медицины

dr.alieva@inbox.ruTyumen State Medical UniversityТюменский государственный медицинский университет2307202542351630012025Copyright ©; 2025, Eco-VectorCopyright ©; 2025, Эко-Вектор2025Eco-VectorЭко-Векторhttps://permmedjournal.ru/PMJ/article/view/649345

The objective of this review is to systematize and summarize the available literature data on the problem of sarcopenia in patients with type 1 diabetes mellitus (DM 1). Sarcopenia is a progressive and generalized disease characterized by loss of muscle mass, strength, and decreased skeletal muscle function. More and more data reflecting the deterioration of a muscle mass condition and decreased muscle function and strength in patients with DM 1 have accumulated over the past few years. A hypothesis concerning impaired muscle condition and function in young patients with DM is put forward, thus, diabetic sarcopenia can be considered as a direct complication of DM 1.

Currently, diagnostics is based on the clinical algorithm proposed in the consensus of the European Working Group on Sarcopenia in Older People in 2019 (EWGSOP2). Despite numerous studies on sarcopenia, the issue of validated biomarkers used for early diagnosis and monitoring of sarcopenia remains unresolved.

Систематизированы и обобщены имеющиеся в литературе данные по проблеме саркопении у пациентов с сахарным диабетом 1-го типа (СД 1). Саркопения – это прогрессирующее и генерализованное заболевание, характеризующееся потерей мышечной массы, силы и снижением функции скелетных мышц. За последние несколько лет все больше накапливается данных, отражающих ухудшение состояния мышечной массы и снижение функции и силы мышц у пациентов с СД 1. Выдвигается гипотеза о нарушении состояния и функционирования мышц у пациентов молодого возраста с СД, таким образом, диабетическая саркопения может рассматриваться как непосредственное осложнение СД 1.

В настоящее время диагностика основана на клиническом алгоритме, предложенном в консенсусе Европейской рабочей группы по саркопении пожилых людей 2019 г. (EWGSOP2). Несмотря на многочисленные исследования, посвященные саркопении, открытым остается вопрос валидированных биомаркеров, используемых для ранней диагностики и мониторинга саркопении.

Sarcopeniatype 1 diabetes mellituscomplications of diabetesСаркопениясахарный диабет 1-го типаосложнения диабетаGandham A., Gregori G., Johansson L., Larsson B.A.M, Johansson H., Harvey N.C., Vandenput L., McCloskey E., Kanis J.A., Litsne H., Axelsson K., Lorentzon M. Sarcopenia definitions and their association with injurious falls in older Swedish women from the Sahlgrenska University Hospital Prospective Evaluation of Risk of Bone fractures (SUPERB) study. Osteoporos Int. 2024; 35 (11): 1963–1972. DOI: 10.1007/s00198-024-07196-0Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., Schneider S.M., Sieber C.C., Topinkova E., Vandewoude M., Visser M., Zamboni M. Writing group for the European working group on sarcopenia in older people 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48 (4): 601. DOI: 10.1093/ageing/afz046Antunes A.C., Araújo D.A., Veríssimo M.T., Amaral T.F. Sarcopenia and hospitalisation costs in older adults: a cross-sectional study. Nutr Diet. 2017; 74 (1): 46–50. DOI: 10.1111/1747-0080.12287Guo J.Y., Yu K., Li C.W., Bao Y.Y., Zhang Y., Wang F., Li R.R., Xie H.Y. The application of Chinese version of SARC-F and SARC-CalF in sarcopenia screening against five definitions: a diagnostic test accuracy study. BMC Geriatr. 2024 Oct 26; 24 (1): 883. DOI: 10.1186/s12877-024-05460-wPetermann-Rocha F., Balntzi V., Gray S.R., Lara J., Ho F.K., Pell J.P., Celis-Morales C. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022; 13 (1): 86–99. DOI: 10.1002/jcsm.12783Petermann-Rocha F., Chen M., Gray S.R., Ho F.K., Pell J.P., Celis-Morales C. Factors associated with sarcopenia: A cross-sectional analysis using UK Biobank. Maturitas. 2020; 133: 60–67. DOI: 10.1016/j.maturitas.2020.01.004Wilkinson D.J., Piasecki M., Atherton P.J. The age-related loss of skeletal muscle mass and function: Measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans. Ageing Res Rev. 2018; 47: 123–132. DOI: 10.1016/j.arr.2018.07.005Sartori R., Romanello V., Sandri M. Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nat Commun. 2021; 12 (1): 330. DOI: 10.1038/s41467-020-20123-1Nishikawa H., Fukunishi S., Asai A., Yokohama K., Nishiguchi S., Higuchi K. Pathophysiology and mechanisms of primary sarcopenia (Review). International Journal of Molecular Medicine. 2021; 48(2): 156. DOI: 10.3892/ijmm.2021.4989Baylis D., Bartlett D.B., Patel H.P., Roberts H.C. Understanding how we age: insights into inflammaging. Longev Healthspan. 2013; 2(8). DOI: 10.1186/2046-2395-2-8Correia-Melo C., Marques F.D., Anderson R., Hewitt G., Hewitt R., Cole J., Carroll B.M., Miwa S., Birch J., Merz A., Rushton M.D., Charles M., Jurk D., Tait S.W., Czapiewski R., Greaves L., Nelson G., Bohlooly-Y M, Rodriguez-Cuenca S., Vidal-Puig A., Mann D., Saretzki G., Quarato G., Green D.R., Adams P.D., von Zglinicki T., Korolchuk V.I., Passos J.F. Mitochondria are required for pro-ageing features of the senescent phenotype. EMBO J. 2016; 35 (7): 724–42. DOI: 10.15252/embj.201592862Merritt E.K., Stec M.J., Thalacker-Mercer A., Windham S.T., Cross J.M., Shelley D.P., Craig Tuggle S., Kosek D.J., Kim J.S., Bamman M.M. Heightened muscle inflammation susceptibility may impair regenerative capacity in aging humans. J Appl Physiol. 1985. 2013; 115 (6): 937–48. DOI: 10.1152/japplphysiol.00019.2013Monaco C.M.F, Gingrich M.A., Hawke T.J. Considering type 1 diabetes as a form of accelerated muscle aging. Exerc Sport Sci Rev. 2019; 47 (2): 98–107. DOI: 10.1249/JES.0000000000000184Kacerovsky M., Brehm A., Chmelik M., Schmid A.I., Szendroedi J., Kacerovsky-Bielesz G., Nowotny P., Lettner A., Wolzt M., Jones J.G., Roden M. Impaired insulin stimulation of muscular ATP production in patients with type 1 diabetes. J Intern Med. 2011; 269 (2): 189–99. DOI: 10.1111/j.1365-2796.2010.02298.xCrowther G.J., Milstein J.M., Jubrias S.A., Kushmerick M.J., Gronka R.K., Conley K.E. Altered energetic properties in skeletal muscle of men with well-controlled insulin-dependent (type 1) diabetes. Am J Physiol Endocrinol Metab. 2003; 284 (4): E655–62. DOI: 10.1152/ajpendo.00343.2002Krause M.P., Riddell M.C., Hawke T.J. Effects of type 1 diabetes mellitus on skeletal muscle: clinical observations and physiological mechanisms. Pediatr Diabetes. 2011; 12 (4 Pt 1): 345–64. DOI: 10.1111/j.1399-5448.2010.00699.xMori H., Kuroda A., Araki M., Suzuki R., Taniguchi S., Tamaki M., Akehi Y., Matsuhisa M. Advanced glycation end-products are a risk for muscle weakness in Japanese patients with type 1 diabetes. J Diabetes Investig. 2017; 8 (3): 377–382. DOI: 10.1111/jdi.12582Lukács A., Mayer K., Juhász E., Varga B., Fodor B., Barkai L. Reduced physical fitness in child¬ren and adolescents with type 1 diabetes. 2012; 13 (5): 432–7. DOI: 10.1111/j.1399-5448.2012.00848.xRobinson M.M., Dasari S., Karakelides H., Bergen H.R. 3rd, Nair K.S. Release of skeletal muscle peptide fragments identifies individual proteins degraded during insulin deprivation in type 1 diabetic humans and mice. Am J Physiol Endocrinol Metab. 2016; 311 (3): E628–37. DOI: 10.1152/ajpendo.00175.2016Andreo-López M.C., Zarco-Martín M.T., Contreras-Bolívar V., Fernández-Soto M.L. Prevalence of sarcopenia and dynapenia and related clinical outcomes in patients with type 1 diabetes mellitus. Nutrients. 2023; 15 (23): 4914. DOI: 10.3390/nu15234914Hiromine Y., Noso S., Rakugi H., Sugimoto K., Takata Y., Katsuya T., Fukuda M., Akasaka H., Osawa H., Tabara Y., Ikegami H. Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: The MUSCLES-DM study. J Diabetes Investig. 2022; 13 (11):1881–1888. DOI: 10.1111/jdi.13882Tan S., Gunendi Z., Meray J., Yetkin İ. The evaluation of muscle strength and architecture in type 1 diabetes mellitus: a cross-sectional study. BMC Endocr Disord. 2022; 22 (1): 153. DOI: 10.1186/s12902-022-01062-yZiaaldini M.M., Marzetti E., Picca A., Murlasits Z. Biochemical pathways of sarcopenia and their modulation by physical exercise: A Narrative Review. Front. Med. 2017; 4: 167. DOI: 10.3389/fmed.2017.00167de Luis Román D., Gómez J.C., García-Almeida J.M., Vallo F.G., Rolo G.G., Gómez J.J.L., Tarazona-Santabalbina F.J., Sanz-Paris A. A proposed muscle screening protocol in peoplewith diabetes: Expert document. Rev Endocr Metab Disord. 2024; 25 (4): 651–661. DOI: 10.1007/s11154-023-09871-9Наумов A.В., Деменок Д.В., Онучина Ю.С., Ховасова Н.О., Мороз В.И., Балаева М.Б. Инструментальная диагностика остеосаркопении в схемах и таблицах. Российский журнал гериатрической медицины 2021; 3: 358–364. DOI: 10.37586/2686-8636-3-2021-350-356 /Naumov A.V., Demenok D.V., Onuchina Yu.S., Khovasova N.O., Moroz V.I., Balaeva M.М. Instrumental diagnosis of osteosarcopenia in diagrams and tables. Russian Journal of Geriatric Medicine 2021; 3: 358–364. DOI: 10.37586/2686-8636-3-2021-350-356 (in Russian).Rentflejsz J., Wojszel Z.B. Diabetes mellitus should be considered while analysing sarcopenia-related biomarkers. J Clin Med. 2024; 13 (4): 1107. DOI: 10.3390/jcm13041107Trendelenburg A.U., Meyer A., Rohner D., Boyle J., Hatakeyama S., Glass D.J. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol. 2009; 296 (6): C1258-70. DOI: 10.1152/ajpcell.00105.2009Bergen H.R. 3rd, Farr J.N., Vanderboom P.M., Atkinson E.J., White T.A., Singh R.J.,Khosla S., LeBrasseur N.K. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle. 2015; 5: 21. DOI: 10.1186/s13395-015-0047-5Han D.S., Chang K.V., Li C.M., Lin Y.H., Kao T.W., Tsai K.S., Wang T.G., Yang W.S. Skeletal muscle mass adjusted by height correlated better with muscular functions than that adjusted by body weight in defining sarcopenia. Sci Rep. 2016; 6: 19457. DOI: 10.1038/srep19457Lee E.J., Ahmad S.S., Lim J.H., Ahmad K., Shaikh S., Lee Y.S., Park S.J., Jin J.O., Lee Y.H., Choi I. Interaction of fibromodulin and myostatin to regulate skeletal muscle aging: An opposite regulation in muscle aging, diabetes, and intracellular lipid accumulation. Cells. 2021; 10 (8): 2083. DOI: 10.3390/cells10082083Dial A.G., Monaco C.M.F, Grafham G.K., Romanova N., Simpson J.A., Tarnopolsky M.A., Perry C.G.R, Kalaitzoglou E., Hawke T.J. Muscle and serum myostatin expression in type 1 diabetes. Physiol Rep. 2020; 8 (13): e14500. DOI: 10.14814/phy2.14500Efthymiadou A., Vasilakis I.A., Giannakopoulos A., Chrysis D. Myostatin serum levels in children with type 1 diabetes mellitus. Hormones (Athens). 2021; 20 (4): 777–782. DOI: 10.1007/s42000-021-00317-yDu Y., Xu C., Shi H., Jiang X., Tang W., Wu X., Chen M., Li H., Zhang X., Cheng Q. Serum concentrations of oxytocin, DHEA and follistatin are associated with osteoporosis or sarcopenia in community-dwelling postmenopausal women. BMC Geriatr. 2021; 21 (1): 542. DOI: 10.1186/s12877-021-02481-7Park H.S., Kim H.C., Zhang D., Yeom H., Lim S.K. The novel myokine irisin: clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women. Endocrine. 2019; 64 (2): 341–348. DOI: 10.1007/s12020-018-1814-yChang J.S., Kim T.H., Nguyen T.T., Park K.S., Kim N., Kong I.D. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. Geriatr Gerontol Int. 2017; 17 (11): 2266–2273. DOI: 10.1111/ggi.13030Komici K., Dello Iacono A., De Luca A., Perrotta F., Bencivenga L., Rengo G., Rocca A., Guerra G. Adiponectin and sarcopenia: A systematic review with meta-analysis. Front Endocrinol (Lausanne). 2021; 12: 576619. DOI: 10.3389/fendo.2021.576619Hubbard R.E., O'Mahony M.S., Calver B.L., Woodhouse K.W. Nutrition, inflammation, and leptin levels in aging and frailty. J Am Geriatr Soc. 2008; 56 (2): 279–84. DOI: 10.1111/j.1532-5415.2007.01548.xGiovannini S., Marzetti E., Borst S.E., Leeuwenburgh C. Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults. Mech Ageing Dev. 2008; 129 (10): 593–601. DOI: 10.1016/j.mad.2008.08.001Bian A., Ma Y., Zhou X., Guo Y., Wang W., Zhang Y., Wang X. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. BMC Musculoskelet Disord. 2020; 21 (1): 214. DOI: 10.1186/s12891-020-03236-yHata S., Mori H., Yasuda T., Irie Y., Yamamoto T., Umayahara Y., Ryomoto K., Yoshiuchi K., Yoshida S., Shimomura I., Kuroda A., Matsuhisa M. A low serum IGF-1 is correlated with sarcopenia in subjects with type 1 diabetes mellitus: Findings from a post-hoc analysis of the iDIAMOND study.Diabetes Res Clin Pract. 2021; 179: 108998. DOI: 10.1016/j.diabres.2021.108998Yanagita I., Fujihara Y., Kitajima Y., Tajima M., Honda M., Kawajiri T., Eda T., Yonemura K., Yamaguchi N., Asakawa H., Nei Y., Kayashima Y., Yoshimoto M., Harada M., Araki Y., Yoshimoto S., Aida E., Yanase T., Nawata H., Muta K. A High Serum Cortisol/DHEA-S Ratio Is a Risk Factor for Sarcopenia in Elderly Diabetic Patients. J Endocr Soc. 2019; 3 (4): 801–813. DOI: 10.1210/js.2018-00271Bano G., Trevisan C., Carraro S., Solmi M., Luchini C., Stubbs B., Manzato E., Sergi G., Veronese N. Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas. 2017; 96: 10–15. DOI: 10.1016/j.maturitas.2016.11.006Tuttle C.S.L, Thang L.A.N, Maier A.B. Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis. Ageing Res Rev. 2020; 64: 101185. DOI: 10.1016/j.arr.2020.101185